R. de Oliveira Lopes et al. / European Journal of Medicinal Chemistry 54 (2012) 264e271
271
[15] J. Dumas, R. Sibley, B. Riedl, M.K. Monahan, W. Lee, T.B. Lowingwe,
A.M. Redman, J.S. Johnson, J. Kingery-Wood, W.J. Scott, R.A. Smith, M. Bobko,
R. Schoenleber, G.E. Ranges, T.J. Housley, A. Bhargava, S.M. Wilhelm,
A. Shrikhande, Discovery of a new class of p38 kinase inhibitors, Bioorg. Med.
Chem. Lett. 10 (2000) 2047e2050.
[16] T. Mizushima, K. Obata, H. Yamanaka, Y. Dai, T. Fukuoka, A. Tokunaga,
T. Mashimo, K. Noguchi, Activation of p38 MAPK in primary afferent neurons
by noxious stimulation and its involvement in the development of thermal
hyperalgesia, Pain 113 (2005) 51e60.
[17] I.G. Ribeiro, K.C.M. Silva, S.C. Parrini, A.L.P. Miranda, C.A.M. Fraga, E.J. Barreiro,
Synthesis and antinociceptive properties of new structurally planned imidazo
[1,2-a] pyridine 3-acylarylhydrazone derivatives, Eur. J. Med. Chem. 33 (1998)
225e235.
[18] A.T. Guerrero, W.A. Verri Jr., T.M. Cunha, T.A. Silva, F.A. Rocha, S.H. Ferreira,
F.Q. Cunha, C.A. Parada, Hypernociception elicited by tibio-tarsal joint flexion
in mice: a novel experimental arthritis model for pharmacological screening,
Pharmacol. Biochem. Behav. 84 (2006) 244e251.
[19] A.C. Brando Lima, A.L. Machado, P. Simon, M.M. Cavalcante, G.M.S. SIilva,
P.G.B.D. Nascimento, L. Quintas, F.Q. Cunha, E.J. Barreiro, V.L.G. Koatz,
L.M. Lima, Anti-inflammatory effects of LASSBio-998, a new drug candidate
designed to be a p38 MAPK inhibitor, in an experimental model of acute lung
inflammation, Pharmacol. Rep. 63 (2011) 1029e1039.
[20] C.D. Duarte, J.L.M. Tributino, D.I. Lacerda, M.V. Martins, M.S. Alexandre-Mor-
eira, F. Dutra, E.J.H. Bechara, F.S. De-Paula, M.O.F. Goulart, J. Ferreira,
J.B. Calixto, M.P. Nunes, A.L. Bertho, A.L.P. Miranda, E.J. Barreiro, C.A.M. Fraga,
Synthesis, pharmacological evaluation and electrochemical studies of novel
6-nitro-3,4-methylenedioxyphenyl-Nacylhydrazone derivatives: discovery of
LASSBio-881, a new ligand of cannabinoid receptors, Bioorg. Med. Chem. 15
(2007) 2421e2433.
[21] R. Gallily, A. Yamin, Y. Waksmann, H. Ovadia, J. Weidenfeld, A. Bar-Joseph,
A. Biegon, R. Mechoulam, E. Shohami, Protection against septic shock and
suppression of tumor necrosis factor alpha and nitric oxide production by
dexanabinol (HU-211), a nonpsychotropic cannabinoid, J. Pharmacol. Exp.
Ther. 283 (1997) 918e924.
[22] T. Mosmann, Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays, J. Immunol. Methods 65
(1983) 55e63.
Acknowledgements
The authors thank CNPq (BR), FAPERJ (BR), CAPES (BR) and
INCT-INOFAR (BR, # 573.564/2008-6 and # E-26/170.020/2008) for
fellowship and financial support.
References
[1] M. Krishna, H. Narang, The complexity of mitogen-activated protein kinases
(MAPKs) made simple, Cell. Mol. Life Sci. 65 (2008) 3525e3544.
[2] R.R. Jia, R.W. Gereau, M. Malcangioc, G.R. Strichartz, MAP kinase and pain,
Brain Res. Rev. 60 (2009) 135e148.
[3] J.D. Ashwell, The many paths to p38 mitogen-activated protein kinase
activation in the immune system, Nat. Rev. Immunol. 6 (2006) 532e540.
[4] L.R. Coulthard, D.E. White, D.L. Jones, M.F. Mcdermott, S.A. Burchill, p38
MAPK: stress responses from molecular mechanisms to therapeutics, Trends
Mol. Med. 15 (2009) 369e379.
[5] A.M. Redman, J.S. Johnson, R. Dally, S. Swartz, H. Wild, H. Paulsen, Y. Caringal,
D. Gunn, J. Renick, M. Osterhout, J. Kingery-Wood, R.A. Smith, W. Lee,
J. Dumas, S.M. Wilhelm, T.J. Housley, A. Bhargava, G.E. Ranges, A. Shrikhande,
D. Young, M. Bombara, W.J. Scott, p38 kinase inhibitors for the treatment of
arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas, Bioorg. Med.
Chem. Lett. 11 (2001) 9e12.
[6] J. Dumas, H. Hatoum-Mokdad, R. Sibley, B. Riedl, W.J. Scott, M.K. Monahan,
T.B. Lowinger, C. Brennan, R. Natero, T. Turner, J.S. Johnson, R. Schoenleber,
A. Bhargava, S.M. Wilhelm, T.J. Housley, G.E. Ranges, A. Shrikhande, 1-Phenyl-
5-pyrazolyl ureas: potent and selective p38 kinase inhibitors, Bioorg. Med.
Chem. Lett. 10 (2000) 2051e2054.
[7] J. Regan, S. Breitfelder, P. Cirillo, T. Gilmore, A.G. Graham, E. Hickey, B. Klaus,
J. Madwed, M. Moriak, N. Moss, C. Pargellis, A. Proto, A. Swinamer, L. Tong,
C. Torcellini, Pyrazole urea-based inhibitors of p38 MAP kinase: from lead
compound to clinical candidate, J. Med. Chem. 45 (2002) 2994e3008.
[8] M.R. Lee, C. Dominguez, MAP kinase p38 inhibitors: clinical results and an
intimate look at their interactions with p38 protein, Curr. Med. Chem. 12
(2005) 2979e2994.
[9] M.L. Verdonk, j.c. Cole, m.j. Hartshorn, c.w. Murray, r.d. Taylor, Improved
protein-ligand docking using GOLD, Proteins 52 (2003) 609e623.
[10] C. Pargellis, L. Tong, L. Churchill, P.F. Cirillo, T. Gilmore, A.G. Graham,
P.M. Grob, E.R. Hickey, N. Moss, S. Pav, J. Regan, Inhibition of p38 MAP kinase
by utilizing a novel allosteric binding site, Nat. Struct. Biol. 4 (2002) 268e272.
[11] E.J. Barreiro, P.R.R. Costa, F.A.S. Coelho, F.M.C. Farias, Prostaglandin analogues.
2. Synthesis of new derivatives from safrole isolated from sassafraz oil,
J. Chem. Res. (S) (1985) 220e221.
[23] C. Canetti, J.S. Silva, S.H. Ferreira, F.Q. Cunha, Tumour necrosis factor-alpha
and leukotriene B4 mediate the neutrophil migration in immune
inflammation, Br. J. Pharmacol. 134 (2001) 1619e1628.
[24] S.B. Su, P.B. Silver, R.S. Grajewski, R.K. Agarwal, J. Tang, C.C. Chan, R.R. Caspi,
Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and
9, in the adjuvant effect promoting Th1-mediated autoimmunity, J. Immunol.
175 (2005) 6303e6310.
[25] H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig,
I.N. Shindyalov, P.E. Bourne, The protein data bank, Nucleic Acids Res. 28
(2000) 235e242.
[12] J.B. Ekeley, M.S. Klemme, The nitration of piperonal, J. Am. Chem. Soc. 50
(1928) 2711e2715.
[13] S.-X. Wang, J.-T. Li, W.-Z. Yang, T.-S. Li, Synthesis of ethyl
a-cyanocinnamates
catalyzed by KF-Al2O3 under ultrasound irradiation, Ultrason. Sonochem. 9
(2002) 159e161.
[14] L. Zhou, S. Tu, D. Shi, G. Dai, Facile and efficient synthesis of 2-aminoquinolone-
3-carboxylic acid derivatives via reductive cyclization of nitro and cyano
groups induced by low-valent titanium, J. Chem. Res. (S) (1998) 398e399.
[26] M.J.S. Dewar, E.G. Zoebisch, E.F. Healy, J.J.P. Stewart, Development and use of
quantum mechanical molecular models. AM1:
a new general purpose
quantum mechanical molecular model, J. Am. Chem. Soc. 107 (1985)
3902e3909.
[27] W.L. Delano, The PyMOL Molecular Graphics System, DeLano Scientific, San
Carlos, CA, 2002.